Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited Ordinary Shares (NY:TEVA)

39.04 -0.09 (-0.22%)
Delayed Quote Updated: 2:20 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Teva Pharmaceutical Industries Limited Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Teva Pharmaceutical (NYSE:TEVA) Nears Breakout With Perfect Technical Rating and Bull Flag Setup ↗
Via Chartmill
News headline image
Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround ↗
Built on substance, not hype, Teva's mega rally is just getting started. 
Via The Motley Fool
News headline image
Teva Eyes New Growth Phase After Securing Investment-Grade Ratings ↗
Teva Pharmaceutical Industries (NYSE:TEVA) is planning for greater financial flexibility after receiving investment-grade ratings from all three major credit rating agencies, President and CEO Richard... 
Via MarketBeat
Topics Bankruptcy
News headline image
Teva CEO Details Biopharma Pivot, $700M Savings Plan and Growth Pipeline ↗
Teva Pharmaceutical Industries (NYSE:TEVA) Chief Executive Officer Richard Francis said the company has shifted from being viewed primarily as a generics manufacturer toward a biopharmaceutical company... 
Via MarketBeat
TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) Flags Technical Breakout Setup with Top Ratings ↗
Via Chartmill
News headline image
Teva Says Pivot to Growth Gains Steam as Branded Drugs, Biosimilars Outperform ↗
Teva Pharmaceutical Industries (NYSE:TEVA) CEO Richard Francis said the company has progressed from the initial phase of its “Pivot to Growth” plan into its next stage, citing momentum in branded... 
Via MarketBeat
Topics World Trade
News headline image
Teva Pharmaceuticals Sees Pivot to Growth Accelerating on Branded Drugs, Biosimilars ↗
Teva Pharmaceutical Industries (NYSE:TEVA) said its “Pivot to Growth” strategy has moved into its second phase, with management pointing to momentum in branded medicines, a stabilized generics... 
Via MarketBeat
News headline image
Teva’s TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study ↗
Teva Pharmaceutical Industries (NYSE:TEVA) reported positive topline results from a Phase IIa gluten-challenge study of TEV-408, its anti-IL-15 antibody candidate for celiac disease, with the company... 
Via MarketBeat
News headline image
Teva (TEVA) Q2 2026 Earnings Call Transcript ↗
Key innovative brands now generate over $1B quarterly revenue. 
Via The Motley Fool
Topics Earnings
News headline image
Why Teva Pharmaceutical Stock Surged This Week ↗
Teva reported its Q2 results this week, but the stock's big gains mostly stemmed from another catalyst. 
Via The Motley Fool
Topics Stocks
News headline image
Teva Pharmaceutical Industries Q2 Earnings Call Highlights ↗
Teva Pharmaceutical Industries (NYSE:TEVA) reported second-quarter 2026 revenue of approximately $4.1 billion, down 1% from a year earlier in U.S. dollars, as lower sales from generic Revlimid were... 
Via MarketBeat
Topics Earnings
News headline image
Teva's Turnaround Is Working. Here's the 1 Thing That Could Send It Soaring Another 50%. ↗
The pharmaceutical company has a likely blockbuster drug as the flagship of its pipeline. 
Via The Motley Fool
News headline image
Wall Street Thinks Teva Can Soar Over 60%. Here's Why Analysts Are Right. ↗
The stock has a 100% buy rating from polled analysts, with some eye-catching price targets. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Teva Pharmaceutical Industries’ Anti-IL-15 Antibody Shows Promise in Vitiligo Study ↗
Teva Pharmaceutical Industries (NYSE:TEVA) said its internally developed anti-IL-15 antibody produced encouraging 24-week efficacy results in a phase 1b proof-of-concept study for vitiligo, as the... 
Via MarketBeat
News headline image
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? ↗
Novartis boasts a 26% net margin and a fortress balance sheet, while Teva's turnaround has returned it to profitability, but at what cost to stability? 
Via The Motley Fool
News headline image
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? ↗
Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion. 
Via The Motley Fool
News headline image
Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain? ↗
Teva has been building its comeback, and the latest studies on Austedo and Austedo XR will help further that momentum. 
Via The Motley Fool
News headline image
Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock? ↗
Driving revenue growth and earnings growth are two different things. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Teva Pharmaceutical Industries Just Pulled Off One of Pharma's Most Impressive Comebacks ↗
Teva's transformation is gaining momentum. 
Via The Motley Fool
News headline image
Teva Stock Is at Its Highest Level in Nearly a Decade. Here's Why It Could Soar Even More. ↗
The market's rediscovery of Teva Pharmaceuticals remains ongoing. 
Via The Motley Fool
News headline image
Wall Street Thinks Teva Stock Still Has Room to Run After Soaring Over 100%. Here's Why Analysts Are Right. ↗
Teva's turnaround is real -- and may not be over. 
Via The Motley Fool
News headline image
Blackstone's $400 Million Bet on Teva: What Does the Smart Money Know That Most Investors Don't? ↗
A significant financing deal with Blackstone underscores that the Teva of today isn't the Teva of the past. 
Via The Motley Fool
News headline image
Teva Pharmaceutical's Turnaround Is Working. Here's When to Buy the Stock. ↗
That's when its first-quarter results will be published. 
Via The Motley Fool
News headline image
3 Catalysts That Could Send Teva Stock to $40 and Beyond ↗
This once-beaten-down pharma stock remains an intriguing turnaround story. 
Via The Motley Fool
News headline image
Neurocrine Biosciences (NBIX): A New Era in Neuroscience and Endocrinology
Date: April 7, 2026 Introduction Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has long been a bellwether for the mid-cap biotechnology sector, serving as a primary case study in how a company can... 
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally
In a month characterized by macroeconomic headwinds and a broader cooling of the biotechnology sector, Corcept Therapeutics (NASDAQ: CORT) has emerged as a definitive outlier. While the S&P Biotech ETF... 
Via MarketMinute
Topics ETFs Intellectual Property Stocks
News headline image
MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough
The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the... 
Via MarketMinute
Topics Intellectual Property
News headline image
The Second Act: A Deep-Dive into Corcept Therapeutics and the FDA Approval of Lifyorli
March 26, 2026 Introduction Yesterday, March 25, 2026, Corcept Therapeutics (NASDAQ: CORT) reached a defining milestone that has fundamentally altered its investment profile: the early FDA approval of... 
Via Finterra
Topics Economy Intellectual Property
News headline image
This $7 Million Masimo Exit Came Before a 34% Surge on $9.9 Billion Acquisition ↗
Masimo develops advanced noninvasive monitoring technologies used by hospitals and healthcare providers worldwide. 
Via The Motley Fool
News headline image
The $1.3 Trillion Architect: How Blackstone is Redefining Global Finance through Private Credit and Essential Consumerism
By Finterra Editorial TeamMarch 18, 2026 Introduction In the high-stakes world of global alternative asset management, one name looms larger than the rest: Blackstone Inc. (NYSE: BX). As of March 18,... 
Via Finterra
Topics Artificial Intelligence Economy Energy
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.